Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
AChE Inhibitor
AChE-IN-7 is a highly selective and potent inhibitor of acetylcholinesterase with an eeAChE IC50 value of 0.045 μM and an eeBuChE IC50 of 19.68 μM. This compound demonstrates promising in vivo and in vitro safety profiles, along with favorable pharmacokinetic characteristics and high bioavailability (F = 55.5%). Additionally, AChE-IN-7 exhibits significant permeability across the blood-brain barrier, making it a valuable tool for research into neurological disorders and therapeutic strategies targeting cholinergic signaling. -
AChE Inhibitor
AChE-IN-44 is a potent acetylcholinesterase (AChE) inhibitor. It effectively enhances cholinergic neurotransmission by inhibiting the breakdown of acetylcholine, making it valuable for research in neurodegenerative diseases such as Alzheimer's. Additionally, AChE-IN-44 can be transformed into the thiazole salt derivative, AChE inhibitor Tat2, expanding its potential applications in pharmacological studies. -
BuChE Inhibitor
BuChE-IN-3 is a selective inhibitor of butyrylcholinesterase (BuChE) with an IC50 of 8.3 nM. This compound demonstrates neuroprotective properties and exhibits mild antioxidant activity, making it suitable for studies related to neurodegenerative diseases. Its favorable lipophilicity and low toxicity profile further support its potential in chemical research applications aimed at exploring BuChE's role in various biological processes. -
Cholinesterase (ChE) Inhibitor
Echimidine N-oxide is a pyrrolizidine alkaloid that serves as an acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 0.347 mM. This compound is utilized in research applications focusing on neurological disorders and cholinergic system modulation. Its inhibitory activity on ChE provides valuable insights into potential therapeutic strategies for conditions associated with cholinergic dysregulation. -
ChEs/MAOs Inhibitor
ChEs/MAOs-IN-2 is a potent inhibitor of cholinesterases and monoamine oxidases, exhibiting IC50 values of 0.10 µM for MAO-A, 0.20 µM for MAO-B, 0.30 µM for acetylcholinesterase (AChE), and 0.40 µM for butyrylcholinesterase (BChE). This compound demonstrates significant biological activity relevant to neurodegenerative diseases, particularly Alzheimer's disease, and serves as a valuable tool for research into therapeutic strategies targeting these enzymes. -
AChE Inhibitor
Scutellarein 4'-methyl ether 7-O-glucuronide is a flavonoid compound that acts as an inhibitor of acetylcholinesterase (AChE), with an IC50 value of 1 mg/mL. Isolated from Plectranthus barbatus, this compound exhibits antioxidant properties and is significant for research into neurological disorders, particularly Alzheimer's disease. Its dual function as an AChE inhibitor and antioxidant makes it valuable for studies exploring therapeutic strategies in cognitive health. -
AChE Inhibitor
Rivastigmine metabolite (NAP 226-90) is an acetylcholinesterase (AChE) inhibitor that plays a significant role in the modulation of cholinergic neurotransmission. This compound is a key metabolite formed in the kidney and is of particular interest for research into Alzheimer's Disease. Its inhibitory action on AChE highlights its potential for studying therapeutic approaches in neurodegenerative conditions characterized by cholinergic deficits. -
Acetylcholinesterase Inhibitor
Protopine hydrochloride is a reversible and competitive inhibitor of acetylcholinesterase. This isoquinoline alkaloid demonstrates significant anti-inflammatory, antimicrobial, anti-angiogenic, and anti-tumor properties. It can be utilized in various research applications, particularly in studies related to neurodegenerative diseases, cancer, and inflammatory disorders. -
AChE Inhibitor
Stemoninine is a lycoris alkaloid that acts as an inhibitor of acetylcholinesterase (AChE), exhibiting a significant inhibitory effect with an IC50 value of 5.52 μM. This compound demonstrates potential antitussive properties, making it a valuable reagent for research involving respiratory conditions and cholinergic signaling pathways. Its ability to modulate AChE activity is important for studies focusing on neurodegenerative diseases and synaptic transmission. -
ChE Inhibitor
Hexafluorenium dibromide is a potent cholinesterase (ChE) inhibitor, exhibiting a pI50 value of 6.96 and a Ki value of 2.4 nM for human plasma cholinesterase. This compound is primarily utilized in research focused on the modulation of cholinergic activity and is relevant for studies investigating neurodegenerative diseases and muscle disorders. Its strong inhibition of ChE makes it a valuable tool for exploring the dynamics of acetylcholine in biological systems. -
AChE/BChE Inhibitor
Octahydroaminoacridine is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), serving as a valuable tool in cholinergic research. Its activity can enhance understanding of neurodegenerative conditions, particularly Alzheimer's disease (AD). This compound offers insight into mechanisms of cholinesterase inhibition, supporting the development of therapeutic strategies for cognitive disorders. -
Acetylcholinesterase Inhibitor
(E)-2-Nitrocinnamic acid is an effective acetylcholinesterase inhibitor. Its primary mechanism of action involves the modulation of acetylcholine levels, which is significant for neurochemical research. This compound is particularly relevant for studies related to Alzheimer's disease and other neurodegenerative disorders, providing valuable insights into potential therapeutic approaches. -
AChE Inhibitor
DCDQ is a potent inhibitor of acetylcholinesterase (AChE), demonstrating strong binding affinity for the 4EY7 protein with a binding energy of −8.2 kcal/mol. This compound is of significant interest in the research of Alzheimer's disease (AD), where AChE inhibition may enhance cholinergic transmission and potentially improve cognitive function. DCDQ serves as a valuable tool for investigating therapeutic strategies aimed at mitigating the effects of neurodegenerative disorders. -
AchE Inhibitor
Territrem C is a potent acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 0.23 μM. This compound, categorized as an α-pyrone meroterpenoid, is derived from the fungus Penicillium sp. SK5GW1L. Territrem C is primarily utilized in biological research to study cholinergic signaling pathways and to explore potential therapeutic strategies for conditions associated with AChE dysfunction. -
AChE/BChE Inhibitor
AChE/BChE-IN-8 is an uncompetitive inhibitor of acetylcholinesterase (AChE) and a mixed inhibitor of butyrylcholinesterase (BChE), demonstrating Ki values of 0.788 μM and 2.364 μM against Electrophorus electricus AChE and equine BChE, respectively. This compound is capable of crossing the blood-brain barrier and exhibits low cytotoxicity, making it suitable for neurological research applications. AChE/BChE-IN-8 can be effectively utilized in studies focused on cholinergic signaling, neurodegenerative diseases, and the modulation of cholinergic activity. -
Cholinesterase Inhibitor
RX 67668 is a potent cholinesterase inhibitor, demonstrating an IC50 of 5 μM for both acetylcholinesterase (AChE) and butyrylcholinesterase. This compound effectively reverses neuromuscular blockade induced by D-tubocurarine. RX 67668 has applications as a muscle relaxant and is utilized in research focused on alleviating skeletal muscle fatigue. -
Acetylcholinesterase Inhibitor
Dehydrogeijerin is a potent inhibitor of acetylcholinesterase, exhibiting an IC50 value of 9.7 μM. This compound is particularly relevant for research into Alzheimer’s disease, where the modulation of acetylcholine levels can influence disease pathology. Dehydrogeijerin's ability to inhibit acetylcholinesterase makes it a valuable tool for exploring therapeutic strategies aimed at enhancing cholinergic signaling in neurodegenerative disorders. -
AChE Inhibitor
AChE-IN-86 is a potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 of 25.33 μg/mL. This compound effectively inhibits AChE by forming hydrogen bonds and π-π and π-alkyl interactions with critical amino acid residues at the enzyme's catalytic sites. AChE-IN-86 is applicable in research focused on Alzheimer's disease, making it a valuable tool for studying cholinergic dysfunction associated with neurodegeneration. -
Acetylcholinesterase Inhibitor
Paecilomide is a pyridone alkaloid that acts as an acetylcholinesterase inhibitor. This compound exhibits key biological activity by enhancing cholinergic signaling, making it significant for research applications related to neurodegenerative diseases such as Alzheimer's. Its ability to inhibit acetylcholinesterase enables the study of cholinergic neurotransmission and potential therapeutic interventions. -
AChE Inhibitor
AChE-IN-25 is a potent and selective uncompetitive inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 2.95 µM. This compound demonstrates significant potential for modulating cholinergic activity, making it a valuable tool in Alzheimer's disease research and related neurodegenerative studies. Its ability to effectively inhibit AChE can aid in understanding and investigating therapeutic strategies targeting cholinergic deficiencies. -
Acetylcholinesterase inhibitor
AChE-IN-37 is an acetylcholinesterase inhibitor featuring an IC50 value of 0.23 μM. This compound modulates reactive oxygen species (ROS) levels and influences the gene expression of NRF2. AChE-IN-37 is applicable in research focused on neurodegenerative diseases and oxidative stress-related studies. -
BChE Inhibitor
Z164597606 is a selective butyrylcholinesterase (BChE) inhibitor, demonstrating IC50 values of 1.3 μM and 1.7 μM for equine and human BChE, respectively. The compound interacts with the enzyme through π-π stacking with the Trp82 residue, facilitating its inhibitory effect. Z164597606 is applicable in research focused on Alzheimer’s disease, enabling investigations into therapeutic strategies targeting cholinesterase activity. -
AChE Inhibitor
AChE-IN-91 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 0.05 μM. It exhibits significant anticholinesterase activity, making it a valuable tool for research into neurological disorders, particularly Alzheimer's disease. This compound facilitates the study of cholinergic signaling and potential therapeutic strategies in neurodegeneration. -
AChE Inhibitor
Isocorydine N-oxide is an alkaloid that functions as an acetylcholinesterase (AChE) inhibitor. This compound exhibits significant activity that may contribute to the modulation of neurotransmitter levels, making it a valuable tool in research focused on neurodegenerative diseases such as Alzheimer's disease. It is utilized to explore therapeutic strategies aimed at enhancing cholinergic function and improving cognitive outcomes in affected individuals. -
BChE Inhibitor
BChE-IN-20 is a potent and selective inhibitor of butyrylcholinesterase (BChE), demonstrating IC50 values of 105 nM for equine BChE and 2.3 nM for human BChE. Additionally, it inhibits P-glycoprotein with an IC50 of 0.27 μM. This compound serves as a valuable template for the design and development of BChE-selective ligands relevant to pharmacological research, including inhibitors and fluorogenic probes. -
BChE Inhibitor
Blestrin D is a potent mixed-type inhibitor of butyrylcholinesterase (BChE), exhibiting an IC50 value of 8.1 μM. Isolated from Bletilla striata, this compound is valuable for investigating the biochemical pathways involved in Alzheimer's disease (AD). Its ability to inhibit BChE makes it an important tool for studying cholinergic dysfunction associated with neurodegenerative conditions. -
AChE Inhibitor
AChE-IN-22 is a selective inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), exhibiting IC50 values of 0.88 μM and 10 μM, respectively. This compound interacts with both the catalytic active site (CAS) and peripheral anionic site (PAS) of AChE, making it a valuable tool for studies related to Alzheimer's disease. AChE-IN-22 is suitable for research applications focused on cholinergic system modulation and neurodegenerative disease mechanisms. -
Cholinesterase (ChE) Inhibitor
eeAChE-IN-2 is a highly potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 2 nM. This compound serves as a valuable tool for studying cholinergic signaling and its modulation in various biological systems. Its application extends to research on neurodegenerative disorders and cognitive function, where AChE inhibition plays a critical role. -
AChE/BChE Inhibitor
AChE/BChE-IN-5 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 266 nM and 10.6 nM against human AChE (hAChE) and human BChE (hBChE), respectively. This compound is capable of crossing the blood-brain barrier (BBB), making it significant for research in neurodegenerative diseases and cognitive disorders. It serves as a valuable tool for studying the modulation of cholinergic signaling and the potential therapeutic effects in conditions such as Alzheimer's disease. -
AChE Inhibitor
Isonaringin is an acetylcholinesterase (AChE) inhibitor that demonstrates potential anti-Alzheimer's activity. By inhibiting AChE, Isonaringin increases acetylcholine levels in the brain, which may help improve cognitive function in neurodegenerative conditions. This compound is relevant for research applications focused on Alzheimer's disease and other related disorders. -
AChE Inhibitor
Zifrosilone is an orally active acetylcholinesterase (AChE) inhibitor, exhibiting a mean maximum inhibition of 20.9% at a dosage of 10 mg. This compound is useful in the study of neurological disorders, providing a valuable tool for research into conditions related to cholinergic dysfunction. Its selective targeting of AChE makes it an important reagent for investigating therapeutic strategies in neurodegenerative diseases. -
AChE Inhibitor
Ambenonium dichloride tetrahydrate is a potent, orally active, reversible inhibitor of acetylcholinesterase (AChE). This compound demonstrates a high affinity for human AChE, with an IC50 value of 0.7 nM, making it valuable for investigations into cholinergic system modulation. Its primary applications include the study of neurodegenerative diseases such as myasthenia gravis and Alzheimer's disease, as well as broader neuropharmacological research. -
BuChE Inhibitor
BuChE-IN-1 is a potent inhibitor of butyrylcholinesterase (BuChE), a key enzyme implicated as a biomarker in the progression of Alzheimer’s disease (AD). This compound exhibits low cytotoxicity and demonstrates excellent permeability across the blood-brain barrier (BBB). BuChE-IN-1 is an advantageous tool for investigating the role of BuChE in AD research and exploring therapeutic interventions. -
AChE Inhibitor
K027 is a potent reactivator of acetylcholinesterase (AChE) inhibited by organophosphates (OP). It effectively restores AChE activity, making it valuable for studying neurodegenerative conditions such as Alzheimer's disease. K027's mechanism and specificity provide a useful tool for investigating therapeutic strategies targeting cholinergic dysfunction. -
Cholinesterase (ChE) Inhibitor
hAChE-IN-4 is a potent inhibitor of human acetylcholinesterase (hAChE) with an IC50 value of 0.25 μM, demonstrating effective permeability across the blood-brain barrier. This compound plays a significant role in research related to Alzheimer's disease, where modulation of cholinergic activity is critical. Its use can aid in exploring therapeutic strategies targeting cholinesterase activity in neurodegenerative disorders. -
AChE Inhibitor
AChE-IN-26 is an acetylcholinesterase (AChE) inhibitor with a reported IC50 of 0.42 μM. This compound plays a significant role in research related to Alzheimer's disease by inhibiting the breakdown of acetylcholine, thereby enhancing cholinergic transmission. AChE-IN-26 serves as a valuable tool for studying pathophysiological mechanisms associated with neurodegeneration and for evaluating potential therapeutic strategies. -
Cholinesterase Inhibitor
Magnotriol B is a potent cholinesterase inhibitor, demonstrating IC50 values of 12.63 nM against acetylcholinesterase (AChE) and 14.5 nM against butyrylcholinesterase (BChE). Additionally, it exhibits notable nitric oxide (NO) inhibitory activity, with an IC50 of 2.02 μM. This compound is applicable in research focused on neurodegenerative disorders and inflammatory diseases, offering potential insights into therapeutic strategies targeting cholinergic dysfunction. -
AChE Inhibitor
Chikusetsusaponin Ib is a potent inhibitor of acetylcholinesterase (AChE), a key enzyme involved in neurotransmission. This compound exhibits significant anti-Alzheimer's disease activity, making it a valuable tool for research focused on neurodegenerative disorders. Its ability to modulate AChE activity can aid in the exploration of therapeutic strategies aimed at enhancing cognitive function and addressing Alzheimer’s pathology. -
AChE Inhibitor
Picfeltarraegenin X is a triterpenoid that functions as an acetylcholinesterase (AChE) inhibitor. This compound exhibits notable biological activity by enhancing acetylcholine levels, making it relevant for studies focused on neurodegenerative disorders such as Alzheimer's disease. Picfeltarraegenin X is useful in research applications aimed at understanding cholinergic signaling and developing potential therapeutic strategies targeting cognitive decline. -
Cholinesterase (ChE) Inhibitor
Cyclopenin is a cholinesterase (ChE) inhibitor that effectively modulates acetylcholine levels by preventing its breakdown. This compound exhibits significant biological activity in the study of neurodegenerative diseases and offers potential applications in the examination of cognitive disorders. Researchers can leverage Cyclopenin’s properties for investigations into synaptic transmission and cholinergic signaling pathways. -
ChE/MAO-A Inhibitor
Desoxypeganine is a potent alkaloid that serves as an inhibitor of cholinesterase (both BChE and AChE) as well as a selective inhibitor of monoamine oxidase A (MAO-A), exhibiting IC50 values of 2, 17, and 2 μM, respectively. This compound is primarily utilized in research related to alcohol abuse, offering valuable insights into the underlying mechanisms of addiction and potential therapeutic approaches. Its dual inhibitory action positions Desoxypeganine as a significant tool in the study of neurochemical pathways involved in substance use disorders. -
Acetylcholinesterase Inhibitor
ω-Hydroxydigitoemodin is an anthraquinone derivative that functions as an acetylcholinesterase inhibitor. This compound exhibits significant anti-acetylcholinesterase activity and has been identified in the marine fungus Trichoderma harzianum XS-20090075. It is utilized in research exploring neurodegenerative diseases and potential therapeutic approaches targeting cholinergic signaling pathways. -
AChE/BChE Inhibitor
AChE/BChE-IN-3 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 6.08 μM and 0.383 μM against electric eel AChE and equine serum BChE, respectively. This compound demonstrates effective inhibition of cholinesterases, which are important targets in studies related to neurodegenerative diseases and pesticide exposure. AChE/BChE-IN-3 is valuable for research applications focused on understanding cholinergic signaling and developing therapeutic strategies for conditions such as Alzheimer's disease. -
AChE Inhibitor
AChE-IN-30 is an acetylcholinesterase (AChE) inhibitor with an IC50 value of 4.4 μM. It exhibits neuroprotective properties by inhibiting H2O2-induced apoptosis through the reduction of intracellular reactive oxygen species (ROS) accumulation. This compound is valuable for research into Alzheimer's disease and related neurodegenerative disorders. -
BChE Inhibitor
Bisnorcymserine is a potent inhibitor of butyrylcholinesterase (BChE) with an IC50 value of 0.228 nM. This compound effectively reduces levels of amyloid-β peptide (Aβ) and has demonstrated therapeutic potential in ameliorating symptoms of Alzheimer's Disease in aged rat models. Bisnorcymserine's ability to penetrate the blood-brain barrier makes it a valuable tool for research in neurodegenerative disorders. -
BChE Inhibitor
BChE-IN-12 is a non-competitive inhibitor of butyrylcholinesterase (BChE) with an IC50 value of 2.3 μM. Isolated from Bletilla striata, this compound demonstrates significant inhibitory activity that can aid in the investigation of cholinergic dysfunction. BChE-IN-12 is particularly relevant for research applications focused on Alzheimer's disease and other cognitive disorders where BChE modulation may play a therapeutic role. -
AChE/BChE Inhibitor
AChE/BChE-IN-4 is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 792 nM for human AChE and 2.2 nM for human BChE. This compound is capable of crossing the blood-brain barrier, making it a valuable tool for research into neurodegenerative diseases such as Alzheimer's. Its selective inhibition profile provides insights into cholinergic system modulation and potential therapeutic applications. -
NTE Inhibitor
KBR 2822 is a selective inhibitor of neurological target esterase (NTE) and exhibits inhibitory activity against acetylcholinesterase (AChE). This compound is utilized in research to investigate the mechanisms of neurological damage and the role of NTE in neurotoxicity. While KBR 2822 can exacerbate neurological damage under specific conditions, it does not induce neurological disease when administered alone without direct neurotoxic effects or biochemical alteration. -
AChE Inhibitor
AChE-IN-8 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 1.95 μM. It is primarily utilized in research focused on Alzheimer's disease, where inhibition of AChE can aid in the enhancement of acetylcholine levels in the synaptic cleft. This compound serves as a valuable tool for investigations into therapeutic strategies for cognitive decline associated with neurodegenerative disorders. -
AChE Inhibitor
ACHE-IN-38 hydrochloride is a potent acetylcholinesterase (AChE) inhibitor that effectively reduces the breakdown of the neurotransmitter acetylcholine. By enhancing cholinergic transmission, this compound shows promise in alleviating memory deficits associated with Alzheimer's Disease. It serves as a valuable tool for research into neurodegenerative disorders and the pharmacological modulation of cognitive functions.
